Prothena(愛(ài)爾蘭)

Prothena

Prothenawww.prothena.comProthenaCorporationplc(PRTA.US)總部位于愛(ài)爾蘭都柏林，前身為「NeotopeCorporationLimited」，2012年10月更為現(xiàn)名，主要從事單克隆抗體藥物的研發(fā)及生產(chǎn)，用于治療帕金森氏癥及轉(zhuǎn)移性癌癥等。ProthenaCorporationplcisaclinicalstagebiotechnologycomp anyfocusedonthediscovery,developmentandcommercializationofnovelantibodiesforthepotentialtreatmentofabroadrangeofdiseasesthatinvolveproteinmisfoldingandcelladhesion,particularlyonthediscovery,developmentandcommercializationofpotentialtherapeuticmonoclonalantibodiesdirectedspecificallytodisease-causingproteins.Thesepotentialtherapieshaveabroadrangeofindications,includingALandAAformsofamyloidosis(NEOD001),Parkinson’sdiseaseandrelatedsynucleinopathies(PRX002),andnovelcelladhesiontargetsinvolvedininflammatorydiseaseandmetastaticcancers(PRX003).Prothenaconductsitsoperationsthroughitswhollyownedsubsidiaries,NeotopeBiosciencesLimited,OnclaveTherapeuticLimite